PP
KLDO

Paloma Partners’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Paloma Partners’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,122
Closed -$75K – 2636
2020
Q2 		$75K Buy
+10,122
New +$67.8K ﹤0.01% 1949

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paloma Partners's KLDO Position: Q3 2020 in Review

Paloma Partners sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2020, closing a stake of 10,122 shares — an estimated $75K sold.

Paloma Partners first reported a position in KLDO in Q2 2020 and held it in 1 quarter. The position peaked at $75K in Q2 2020. 56 funds tracked by Wall St. Rank hold KLDO as of Q3 2020.

  • Paloma Partners reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 10,122 Kaleido Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $75K.
  • Paloma Partners first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Paloma Partners's Kaleido Biosciences, Inc. Common Stock position peaked at $75K in Q2 2020.
  • 56 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.